Association of warfarin use with valvular and vascular calcification: A review

Clinical Cardiology

Volumn 34, Issue 2, 2011, Pages 74-81

  Palaniswamy, Chandrasekar ^a   Sekhri, Arunabh ^a   Aronow, Wilbert S ^a   Kalra, Ankur ^b   Peterson, Stephen J ^a  

^a NEW YORK MEDICAL COLLEGE   (United States)

^b UMDNJ Robert Wood Johnson Medical School at Camden   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; ATORVASTATIN; BISPHOSPHONIC ACID DERIVATIVE; CARBOXYLASE; CERIVASTATIN; CLODRONIC ACID; DABIGATRAN; ENOXAPARIN; ETIDRONIC ACID; FARNOQUINONE; FATTY ACID BINDING PROTEIN; GAMMA CARBOXYLASE; GLUTAMIC ACID; GROWTH ARREST SPECIFIC PROTEIN 6; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IBANDRONIC ACID; OSTEOCALCIN; OSTEOPROTEGERIN; PHYTOMENADIONE; PROTEIN C; PROTEIN S; RIVAROXABAN; UNCLASSIFIED DRUG; VITAMIN K GROUP; WARFARIN;

ANTICOAGULATION; BLOOD VESSEL CALCIFICATION; CALCIFICATION; CARBOXYLATION; DRUG MECHANISM; DRUG MEGADOSE; DRUG WITHDRAWAL; HEART VALVE CALCIFICATION; HUMAN; HYPERBARIC OXYGEN; NONHUMAN; REVIEW;

ANTICOAGULANTS; CALCINOSIS; DIPHOSPHONATES; HEART VALVE DISEASES; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERBARIC OXYGENATION; MUSCLE, SMOOTH, VASCULAR; OSTEOPROTEGERIN; VITAMIN K; WARFARIN;

EID: 79751490206     PISSN: 01609289     EISSN: 19328737     Source Type: Journal    
DOI: 10.1002/clc.20865     Document Type: Review

References (38)

1. Douketis JD, Berger PB, Dunn AS, et al. American College of Chest Physicians. The perioperative management of antithrombotic therapy: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest. 2008; 133 (suppl 6): S299-S339.
2. Shearer MJ, Newman P., Metabolism and cell biology of vitamin K. Thromb Haemost. 2008; 100: 530-547.
3. Cranenburg EC, Schurgers LJ, Vermeer C., Vitamin K: the coagulation vitamin that became omnipotent. Thromb Haemost. 2007; 98: 120-125. (Pubitemid 47074186)
4. Johnson RC, Leopold JA, Loscalzo J., Vascular calcification: pathobiological mechanisms and clinical implications [published correction appears in Circ Res. 2009;105:e8]. Circ Res. 2006; 99: 1044-1059. (Pubitemid 44729928)
5. Luo G, Ducy P, McKee MD, et al. Spontaneous calcification of arteries and cartilage in mice lacking matrix GLA protein. Nature. 1997; 385: 78-81. (Pubitemid 27130923)
6. Howe AM, Webster WS., Warfar in exposure and calcification of the arterial system in the rat. Int J Exp Pathol. 2000; 81: 51-56. (Pubitemid 30171501)
7. Price PA, Faus SA, Williamson MK., Warfarin causes rapid calcification of the elastic lamellae in rat arteries and heart valves. Arterioscler Thromb Vasc Biol. 1998; 18: 1400-1407. (Pubitemid 28421877)
8. Price PA, Faus SA, Williamson MK., Warfarin-induced artery calcification is accelerated by growth and vitamin D. Arterioscler Thromb Vasc Biol. 2000; 20: 317-327. (Pubitemid 30086086)
9. Price PA, Chan WS, Jolson DM, et al. The elastic lamellae of devitalized arteries calcify when incubated in serum: evidence for a serum calcification factor. Arterioscler Thromb Vasc Biol. 2006; 26: 1079-1085. (Pubitemid 43732115)
10. Sweatt A, Sane DC, Hutson SM, et al. Matrix Gla protein (MGP) and bone morphogenetic protein-2 in aortic calcified lesions of aging rats. J Thromb Haemost. 2003; 1: 178-185.
11. Coates T, Kirkland GS, Dymock RB, et al. Cutaneous necrosis from calcific uremic arteriolopathy. Am J Kidney Dis. 1998; 32: 514-518.
12. Spronk HM, Soute BA, Schurgers LJ, et al. Matrix Gla protein accumulates at the border of regions of calcification and normal tissue in the media of the arterial vessel wall. Biochem Biophys Res Commun. 2001; 289: 485-490. (Pubitemid 33141080)
13. Schori TR, Stungis GE., Long-term warfarin treatment may induce arterial calcification in humans: case report. Clin Invest Med. 2004; 27: 107-109. (Pubitemid 38979944)
14. Verdalles Guzmán U, de la Cueva P, Verde E, et al. Calciphylaxis: fatal complication of cardiometabolic syndrome in patients with end stage kidney disease [in Spanish]. Nefrologia. 2008; 28: 32-36.
15. Villines TC, O'Malley PG, Feuerstein IM, et al. Does prolonged warfarin exposure potentiate coronary calcification in humans? Results of the warfarin and coronary calcification study. Calcif Tissue Int. 2009; 85: 494-500.
16. Schurgers LJ, Aebert H, Vermeer C, et al. Oral anticoagulant treatment: friend or foe in cardiovascular disease? Blood. 2004; 104: 3231-3232. (Pubitemid 39507140)
17. Koos R, Mahnken AH, Mühlenbruch G, et al. Relation of oral anticoagulation to cardiac valvular and coronary calcium assessed by multislice spiral computed tomography. Am J Cardiol. 2005; 96: 747-749. (Pubitemid 41317640)
18. Koos R, Krueger T, Westenfeld R, et al. Relation of circulating Matrix Gla-Protein and anticoagulation status in patients with aortic valve calcification. Thromb Haemost. 2009; 101: 706-713.
19. Holden RM, Sanfilippo AS, Hopman WM, et al. Warfarin and aortic valve calcification in hemodialysis patients. J Nephrol. 2007; 20: 417-422. (Pubitemid 350081495)
20. Yamamoto K, Yamamoto H, Yoshida K, et al. Prognostic factors for progression of early-and late-stage calcific aortic valve disease in Japanese: the Japanese Aortic Stenosis Study (JASS) Retrospective Analysis. Hypertens Res. 2010; 33: 269-274.
21. Lerner RG, Aronow WS, Sekhri A, et al. Warfarin use and the risk of valvular calcification. J Thromb Haemost. 2009; 7: 2023-2027.
22. Hara K, Kobayashi M, Akiyama Y., Comparison of inhibitory effects of warfarin on gamma-carboxylation between bone and liver in rats. J Bone Miner Metab. 2005; 23: 366-372. (Pubitemid 41223799)
23. Banerjee C, Woller SC, Holm JR, et al. Atypical calciphylaxis in a patient receiving warfarin then resolving with cessation of warfarin and application of hyperbaric oxygen therapy. Clin Appl Thromb Hemost. 2010; 16: 345-350.
24. Palaniswamy C, Selvaraj DR, Selvaraj T, et al. Mechanisms underlying pleiotropic effects of statins. Am J Ther. 2010; 17: 75-78.
25. Kizu A, Shioi A, Jono S, et al. Statins inhibit in vitro calcification of human vascular smooth muscle cells induced by inflammatory mediators. J Cell Biochem. 2004; 93: 1011-1019. (Pubitemid 44264154)
26. Liu C, Wan J, Yang Q, et al. Effects of atorvastatin on warfarin-induced aortic medial calcification and systolic blood pressure in rats. J Huazhong Univ Sci Technolog Med Sci. 2008; 28: 535-538.
27. Li H, Tao HR, Hu T, et al. Atorvastatin reduced calcification in rat arteries and vascular smooth muscle cells. Basic Clin Pharmacol Toxicol. 2010; 107: 798-802.
28. Yang S, Zhou JZ, Chen YH., Effects of atorvastatin calcium on osteopontin in renovascular hypertensive rats [in Chinese]. Beijing Da Xue Xue Bao. 2010; 42: 147-150.
29. Francis MD, Russell RG, Fleisch H., Diphosphonates inhibit formation of calcium phosphate crystals in vitro and pathological calcification in vivo. Science. 1969; 165: 1264-1266.
30. Fleisch HA, Russell RG, Bisaz S, et al. The inhibitory effect of phosphonates on the formation of calcium phosphate crystals in vitro and on aortic and kidney calcification in vivo. Eur J Clin Invest. 1970; 1: 12-18.
31. Price PA, Faus SA, Williamson MK., Bisphosphonates alendronate and ibandronate inhibit artery calcification at doses comparable to those that inhibit bone resorption. Arterioscler Thromb Vasc Biol. 2001; 21: 817-824. (Pubitemid 32448773)
32. Toussaint ND, Lau KK, Strauss BJ, et al. Effect of alendronate on vascular calcification in CKD stages 3 and 4: a pilot randomized controlled trial. Am J Kidney Dis. 2010; 56: 57-68.
33. Price PA, June HH, Buckley JR, et al. Osteoprotegerin inhibits artery calcification induced by warfarin and by vitamin D. Arterioscler Thromb Vasc Biol. 2001; 21: 1610-1616. (Pubitemid 34215580)
34. Schurgers LJ, Spronk HM, Soute BA, et al. Regression of warfarin-induced medial elastocalcinosis by high intake of vitamin K in rats. Blood. 2007; 109: 2823-2831. (Pubitemid 46482077)
35. Reynolds JL, Joannides AJ, Skepper JN, et al. Human vascular smooth muscle cells undergo vesicle-mediated calcification in response to changes in extracellular calcium and phosphate concentrations: a potential mechanism for accelerated vascular calcification in ESRD. J Am Soc Nephrol. 2004; 15: 2857-2867. (Pubitemid 41103395)
36. Proudfoot D, Davies JD, Skepper JN, et al. Acetylated low-density lipoprotein stimulates human vascular smooth muscle cell calcification by promoting osteoblastic differentiation and inhibiting phagocytosis. Circulation. 2002; 106: 3044-3050. (Pubitemid 35440286)
37. Ronden JE, Drittij-Reijnders MJ, Vermeer C, et al. Intestinal flora is not an intermediate in the phylloquinone-menaquinone-4 conversion in the rat. Biochim Biophys Acta. 1998; 1379: 69-75. (Pubitemid 28045556)
38. Spronk HM, Soute BA, Schurgers LJ, et al. Tissue-specific utilization of menaquinone-4 results in the prevention of arterial calcification in warfarin-treated rats. J Vasc Res. 2003; 40: 531-537. (Pubitemid 38186463)